单次灌胃杂色曲霉素对小鼠大脑细胞的影响

目的　探讨单次ig杂色曲霉素 (ST)对小鼠大脑细胞的影响。方法　采用形态学观察和流式细胞术定量检测方法 ,研究ST对BALB/c小鼠大脑神经细胞的影响。结果　病理形态学观察可见 ,ig小剂量ST(3μg·kg-1 )后 1 2h或大剂量ST(3mg·kg-1 )后6h即可见小鼠大脑皮质、丘脑、海马CA2区神经元出现胞核固缩深染、胞浆嗜酸性变、空泡变性等病理变化 ,且随剂量增大和作用时间延长 ,病变神经元逐渐增多 ;光镜下对海马CA2区病变神经元进行计数分析 ,结果表明ST处理组发生病理变化的神经元比例均高于相应对照组 ,且呈剂量和时间依赖性增高 ;流式细胞术定量检测结果表明 ,igST 3,30 ,30 0和30 0 0 μg·kg-1 1 2h后 ,小鼠脑细胞的凋亡率呈剂量依赖性增高 ;ig3mg·kg-1 的ST后 6～48h,随ST作用时间的延长 ,脑细胞凋亡率也明显增高。结论经口给予ST可导致小鼠大脑皮质、丘脑、海马CA2区神经元发生退行性病变 ,诱导并促进小鼠大脑细胞凋亡     

A Quality and Cost-Benefit Analysis of Dialyzer Reuse in Hemodialysis Patients

Background. To evaluate the benefits of dialyzer reuse for hemodialysis (HD) patients, including the cost of HD treatment and patient's survival, a comparison was made regarding the standard practice of single-use dialysis. Methods. From January 1, 2005, to December 31, 2005, a total of 128,232 successive HD treatments in 822 patients in Chang Gung Memorial Hospital-Kaohsiung Medical Center were included in this study. Results. Approximately 54.25% (446/822) of patients reused dialyzers. The average times of dialyzer reuse was 2.54. The annual hollow fiber cost is reduced by $241,054.08 U.S. dollars (NT $7,834,257.60). The annual cost of hollow fiber was reduced by $540.48 U.S. dollars (NT $17,565.60) in one patient with dialyzer reuse. The mortality rates in dialyzer reuse and single use groups were 3.1% and 10.9% within one year (p < 0.0001). Multiple logistic regressions showed that single use compared with reuse was associated with higher mortality after adjusting co-morbid conditions including age, diabetes mellitus, etc. Conclusions. We concluded that the benefits of dialyzer reuse included safety in our center and reduction in cost during a 12-month period. Dialyzer reuse may be a safe alternative.     

Treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: the role of corticosteroids

We aimed to evaluate the treatments, particularly the role of corticosteroids, in patients with late-onset hemorrhagic cystitis (LOHC) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). One hundred and sixty-three consecutive patients who underwent non-T-cell-depleted allo-HSCT and met the criterion of LOHC after allo-HSCT were enrolled in this study. The median time from allo-HSCT to the occurrence of LOHC was 29 (range, 4–155) days. Pathogens identified in blood and/or urine samples from 143 patients were mostly viruses. All of the patients with LOHC received intravenous fluid hydration, alkalization, and forced diuresis, of which 2 patients achieved complete remission (CR) after these treatments. The remaining 161 patients received anti-infection therapies and 71 achieved CR after the therapies. Corticosteroids were additionally applied to 83 out of 90 patients who did not achieve CR after anti-infection therapies, and 88.0% (n?=?73) of them showed a grade 3 to 4 LOHC at the beginning of corticosteroid therapy. Thirty-five patients showed an immediate response (CR or downgraded at least one grade) within 1 week after the beginning of the corticosteroid therapy. Sixty-four patients (77.1%) achieved CR after corticosteroid therapy, and the median period from the beginning of corticosteroid therapy to CR was 17 days. Thus, we observed that viruses were the most common pathogens in LOHC after allo-HSCT and that anti-infection therapies were critical. For patients not showing a satisfactory response to anti-infection therapies, additional corticosteroid therapy may help to achieve CR.     

重复经颅磁刺激治疗帕金森病2年随访

目的随访观察重复经颅磁刺激(r TMS)治疗帕金森病(PD)患者的疗效。方法应用统一PD评分量表第Ⅲ部分(UPDRSⅢ)、Hoehn-Yahr(H-Y)分级、PD非运动症状(NMS)筛查问卷(NMSQ)、PD睡眠量表(PDSS)、汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)和简易智能量表(MMSE)对37例应用药物和r TMS治疗的PD患者(r TMS+药物组)及45例单纯药物治疗的PD患者(药物组)在基线和2年随访末的运动症状(MS)和非运动症状(NMS)进行评估,对比分析两组患者病情进展。结果 r TMS+药物组2年随访末H-Y分级较基线显著升高(P 0.05);药物组2年随访末UPDRSⅢ、H-Y分级、HAMD、HAMA评分及左旋多巴等效剂量(LED)较基线均显著升高(P 0.05);对两组2年随访末的症状进行比较,药物组的UPDRSⅢ、H-Y分级、HAMD评分及LED较r TMS+药物组升高显著(P 0.05)。结论规律的r TMS辅助常规抗PD药物治疗可减缓PD进展,优于单纯抗PD药物治疗。     

Hyperhomocystinemia and the prevalence of symptomatic atherosclerotic vascular disease in Taiwanese chronic hemodialysis patients: a retrospective study

AIM: Hyperhomocystinemia is now recognized as an independent risk factor for atherosclerotic cardiovascular disease in patients with normal renal function. Hyperhomocystinemia is common in patients with chronic renal failure. This aim of this study was designed to look for associations between hyperhomocystinemia and clinically symptomatic atherosclerotic vascular disease (ASVD) in Taiwanese chronic hemodialysis patients. METHODS: Two hundred patients undergoing hemodialysis were enrolled in the study. They had predialysis blood work performed for total homocysteine, serum folate, and vitamin B12 levels. A history of clinically significant ASVD was elicited using information from the patients' questionnaires and verified by careful inpatient and outpatient chart review. RESULTS: Mean homocysteine concentration was 29.0 micromol/L overall. A total of 196 patients had hyperhomocystinemia and were enrolled in this study. ASVD was present in 24.5% of patients. The mean homocysteine concentration was 31.9 micromol/L and 28.7 micromol/L in patients with (n = 48) and without (n = 148) ASVD, respectively (P = 0.04). There was association hyperhomocystinemia between chronic hemodialysis patients with ASVD and without ASVD. There were significant differences including age, homocysteine level, vitamin B12 level and glucose intolerance in the two groups (P < 0.05). Plasma homocysteine concentrations showed significant positive correlations with serum folate or vitamin B12 in majority patients. No patient had serum folate or vitamin B12 deficiency. The adjusted odds ratio for atherosclerotic disease was 2.8 (95% CI, 1.109-7.467) for those subjects with a homocysteine level in the highest quartile compared with the lowest 3 quartiles. CONCLUSIONS: The prevalence of hyperhomocystinemia is 98% among hemodialysis patients. There is a significant association between hyperhomocystinemia and ASVD in Taiwanese chronic hemodialysis patients. There are also associations between homocysteine levels and serum folate/vitamin B12 levels in the majority of the patients. Clinical trials are needed to determine the optimal therapy of folic acid dose for hyperhomocystinemia in Taiwanese chronic hemodialysis patients in the future.     

E2F3,MCM2及HIF-1α在结直肠癌中的表达及其相关性

目的:探讨转录因子E2F3、微型染色体维持蛋白(minichromosome maintenance proteins 2,MCM2)及缺氧诱导因子1a(hypoxia-induciblefactor 1α,HIF-1α)在结直肠癌、结直肠腺瘤、大肠正常黏膜组织中的表达及他们与结直肠癌临床病理因素之间的关系.方法:收集...     

Comparison of Iodixanol and Iohexol in Patients Undergoing Intravenous Pyelography: A Prospective Controlled Study

Background. Nephropathy associated with contrast medium exposure is a well-known complication of IVP. However, it is uncertain whether iso-osmolar non-iodinated contrast medium (iodixanol) is less nephrotoxic than low-osmolar contrast medium (iohexol). Materials and Methods. In this single-center, double-blind, prospective study, 50 patients undergoing IVP were randomized into two groups receiving different contrast medium: iodixanol and iohexol. Patients in high risk for contrast nephropathy were included, 28 with renal insufficiency and 19 with diabetes mellitus. We compared the nephrotoxic effect (contrast nephropathy), complement and cytokines profile between the iodixanol and iohexol groups. The mean volume of contrast medium in each IVP procedure was 0.8 mL/kg. Results. The incidence of contrast nephropathy was 4 percent among all patients (one iodixanol and one iohexol). We found no significant differences in contrast nephropathy and allergic reactions between the two groups. There was no significant difference in cytokine profiles in both groups (p > 0.05).The incidence of allergic reaction was 16 percent among all patients. Twelve percent (3/25) had late reaction after iohexol exposure compared to four percent (2/25) with iodixanol (p = 1.0). One patient had severe skin rash due to late adverse reaction after iodixanol. No mortality was found. Conclusions. New iodixanol and iohexol contrast medium for routine IVP examination are safe and have low nephrotoxicity profile, especially in elderly or high-risk patients. Iodixanol contrast medium has an increased risk to induce severe late adverse reaction compared to iohexol. Allergic reaction may be the main adverse effect after contrast medium infusion.     

亲水性软性角膜接触镜在准分子激光屈光性角膜手术中的应用

目的:了解亲水性软性角膜接触镜作为物理屏障在准分子激光屈光性角膜手术的作用。方法:对临床观察23例(40眼)准分子激光屈光性角膜切削术后配戴角膜接触镜者进行观察,包括各种临床症状;角膜上皮愈合及角膜瓣对位等,平均配戴1～15d,术后随诊1～3mo。结果:术后配戴角膜接触镜,患者角膜上皮愈合不适症状减轻,角膜瓣无1例发生移位,对位好。结论:准分子激光屈光性角膜手术中及术后早期配戴角膜接触镜具有促进角膜上皮愈合,稳定角膜瓣的作用。     

Prognostic value of acute physiology and chronic health evaluation II and organ system failure in patients with acute renal failure requiring dialysis

BACKGROUND: Despite advances in modern technology of dialysis, prognosis of patients with acute renal failure (ARF) remains poor. To give the clinicians the most useful information, a model that accurately predicts outcome early in the course of ARF is required. However, because ARF is a heterogeneous syndrome and occurs in patients with diverse etiologies and some coexisting diseases, predicting outcome early is hard. The aim of this study is to evaluate prospectively the Acute Physiology and Chronic Health Evaluation (APACHE II) and organ system failure (OSF) models, evaluated prior to dialysis, in predicting hospital mortality. METHODS: From June 2002 to March 2004, ARF patients requiring dialysis at Chang Gung Memorial Hospital, Chiayi, were prospectively recruited for this study. The worst clinical and laboratory data in the 24 hours before initiation of dialysis were prospectively evaluated, and the patients' APACHE II score and OSF number were assessed. RESULTS: A total of 61 patients (40 male and 21 female) were enrolled, of whom 38 (62.3%) died before discharge. By multivariate logistic regression, the APACHE II score (odds ratio 1.3 per increase in one score; P<0.001), or OSF number (odds ratio 1.9 per increase in one OSF; P<0.01) and oliguria (odds ratio 4.2; P=0.04), were found to be statistically significant prognostic factors for hospital mortality. Mortality increased progressively and significantly as OSF number (chi-square for trend; P=0.001) or the APACHE II score (chi-square for trend; P < 0.001) increased. By using Youden's index, the best cut-off value for APACHE II was 24, with 63% sensitivity and 96% specificity. The best cut-off value for OSF number was 2, with a sensitivity of 81.6% and a specificity of 60.9%. The areas under the receiver operating characteristic curves for APACHE II and OSF number were 0.847 (95% confidence interval (CI)=0.752-0.942; P<0.01) and 0.769 (95% CI=0.646-892; P<0.001), respectively, indicating good model discrimination. CONCLUSIONS: This study concludes that APACHE II and OSF number measured prior to initiation of dialysis reliably predict outcomes of ARF patients requiring dialysis. The mortality rates increase as the APACHE II score or OSF number increases. For predicting mortality, the APACHE II score > or = 24 was found to have 63% sensitivity and 96% specificity, and OSF number> or = 2 had 81.6% sensitivity and 60.9% specificity.     

Purple urine bag syndrome in a hemodialysis patient

Purple urine bag syndrome (PUBS) is an uncommon disorder, in which the plastic disposable urinary catheter bag turns purple or blue following hours or days of urinary catheterization. The purple discoloration results from indirubin dissolved in the plastic mixing with indigo in the urine. Bacteria possessing indoxyl sulfatase degrade indoxyl sulfate into indirubin and indigo. Indoxyl sulfate is derived from the metabolism of tryptophan. PUBS usually occurs in chronic catheterized elderly women who are constipated and poorly ambulant. The clinical course is benign and rarely causes sepsis. This investigation reports a 61-year-old female diabetic patient with end-stage renal disease on maintenance hemodialysis, who had two episodes of blue or purple urine bag discoloration. The urine culture of the first episode yielded Klebsiella pneumoniae, whereas that of the second episode yielded Escherichia coli, Enterococcus faecalis, and Proteus vulgaris. Both episodes resolved following oral antibiotics treatment and placement of new foley catheters. To our knowledge, this is the first recorded case of PUBS in a dialysis patient.